Karin Berger

11.1k total citations · 4 hit papers
160 papers, 8.7k citations indexed

About

Karin Berger is a scholar working on Epidemiology, Hematology and Economics and Econometrics. According to data from OpenAlex, Karin Berger has authored 160 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Epidemiology, 27 papers in Hematology and 18 papers in Economics and Econometrics. Recurrent topics in Karin Berger's work include Hemophilia Treatment and Research (20 papers), Health Systems, Economic Evaluations, Quality of Life (15 papers) and Hepatitis C virus research (10 papers). Karin Berger is often cited by papers focused on Hemophilia Treatment and Research (20 papers), Health Systems, Economic Evaluations, Quality of Life (15 papers) and Hepatitis C virus research (10 papers). Karin Berger collaborates with scholars based in Germany, United States and United Kingdom. Karin Berger's co-authors include Q L Choo, C. Kuo, George Kuo, Michael Houghton, Jang H. Han, Jeffrey R. Shuster, Doris Coit, Christine Dong, P J Barr and Carmen Gallegos and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Karin Berger

140 papers receiving 8.2k citations

Hit Papers

An Assay for Circulating ... 1989 2026 2001 2013 1989 1991 1994 2015 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. An Assay for Circulating Antibodies to a Major Etiologic Virus of Human Non-A, Non-B Hepatitis
    1989 2.7k citations Karin Berger, Michael Houghton et al. profile →
  2. Genetic organization and diversity of the hepatitis C virus.
    1991 1.5k citations Karin Berger et al. profile →
  3. Vaccination of chimpanzees against infection by thehepatitis C virus.
    1994 468 citations Karin Berger et al. profile →
  4. Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence
    2015 332 citations Karin Berger et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Karin Berger 5.1k 4.4k 1.1k 864 819 160 8.7k
Éric Rosenthal 1.4k 0.3× 4.1k 0.9× 639 0.6× 571 0.7× 176 0.2× 287 8.7k
Françoise Roudot‐Thoraval 4.0k 0.8× 4.4k 1.0× 351 0.3× 1.2k 1.4× 102 0.1× 239 10.7k
Giovanni Casazza 2.0k 0.4× 2.8k 0.6× 681 0.6× 238 0.3× 116 0.1× 181 5.7k
Junko Tanaka 2.4k 0.5× 2.5k 0.6× 320 0.3× 449 0.5× 104 0.1× 317 4.7k
Harold O. Conn 7.0k 1.4× 6.0k 1.4× 168 0.2× 530 0.6× 406 0.5× 211 11.3k
Nancy Agmon‐Levin 479 0.1× 1.5k 0.3× 568 0.5× 668 0.8× 731 0.9× 179 7.8k
Qin Ning 1.4k 0.3× 2.3k 0.5× 171 0.2× 1.5k 1.8× 1.8k 2.2× 209 8.7k
Robert J. de Knegt 4.5k 0.9× 5.1k 1.2× 374 0.4× 541 0.6× 54 0.1× 235 7.2k
Fernando Álvarez 4.4k 0.9× 3.8k 0.9× 184 0.2× 438 0.5× 171 0.2× 259 7.4k
Manuel Pascual 1.4k 0.3× 2.7k 0.6× 179 0.2× 899 1.0× 178 0.2× 266 10.6k

Countries citing papers authored by Karin Berger

Since Specialization
Citations

This map shows the geographic impact of Karin Berger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Berger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Berger more than expected).

Fields of papers citing papers by Karin Berger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Berger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Berger. The network helps show where Karin Berger may publish in the future.

Co-authorship network of co-authors of Karin Berger

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Berger. A scholar is included among the top collaborators of Karin Berger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Berger. Karin Berger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Berger, Karin, Peter Buggisch, Julia Mayerle, et al.. (2024). 195P Risk factors in patients with hepatocellular carcinoma: A German claims data analysis. Annals of Oncology. 35. S87–S87. 1 indexed citations
2.
3.
4.
Berger, Karin, et al.. (2024). Long-term effects of doping with anabolic steroids during adolescence on physical and mental health. Die Orthopädie. 53(8). 608–616. 7 indexed citations
5.
Berger, Karin, Matteo Nicola Dario Di Minno, Angelika Bátorová, et al.. (2024). Challenges associated with access to recently developed hemophilia treatments in routine care: perspectives of healthcare professionals. Haematologica. 110(3). 673–682. 1 indexed citations
6.
7.
Ellenberger, David, et al.. (2022). Adverse events in MS patients fulfilling or not inclusion criteria of the respective clinical trial – The problem of generalizability. Multiple Sclerosis and Related Disorders. 69. 104422–104422. 3 indexed citations
8.
Berger, Karin, et al.. (2018). Burden of Oral Mucositis: A Systematic Review and Implications for Future Research. Oncology Research and Treatment. 41(6). 399–405. 66 indexed citations
9.
Ehlken, B., et al.. (2014). Current Guidance for Brca Mutation Testing in Ovarian Cancer Patients. Value in Health. 17(7). A663–A663. 1 indexed citations
10.
Berger, Karin, et al.. (2011). The Wildbad Kreuth initiative: European current practices and recommendations for optimal use of blood components. Biologicals. 39(3). 189–193. 6 indexed citations
11.
12.
Wilkens, Heinrike, Friedrich Grimminger, Marius M. Hoeper, et al.. (2010). Burden of pulmonary arterial hypertension in Germany. Respiratory Medicine. 104(6). 902–910. 40 indexed citations
13.
Ihbe‐Heffinger, Angela, B. Ehlken, Karin Berger, et al.. (2004). The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Annals of Oncology. 15(3). 526–536. 113 indexed citations
14.
Szucs, Thomas D., Matthias Schwenkglenks, Karin Berger, & Karl R. Karsch. (2003). Kosten und Kosteneffektivität von Eptifibatid in der Behandlung des akuten Koronarsyndroms. Zeitschrift für Kardiologie. 92(3). 236–244. 5 indexed citations
15.
Szucs, Thomas D., Karin Berger, David N. Fisman, & Stephan Harbarth. (2001). The estimated economic burden of genital herpes in the United States. An analysis using two costing approaches. BMC Infectious Diseases. 1(1). 5–5. 40 indexed citations
16.
Harbarth, Stephan, Thomas D. Szucs, Karin Berger, & Wolfgang Jilg. (2000). The economic burden of Hepatitis B in Germany. European Journal of Epidemiology. 16(2). 173–177. 25 indexed citations
17.
Szucs, Thomas D., et al.. (1998). Pharmakoökonomische Bewertung von Pravastatin in der Sekundärprävention der koronaren Herzkrankheit bei Patienten mit durchschnittlichen Cholesterinwerten : Eine Analyse für Deutschland auf der Grundlage der CARE-Studie (Aus Aktuellem Anlass). Herz. 23(5). 319–329. 2 indexed citations
18.
Berger, Karin, Gerald Klose, & Thomas D. Szucs. (1997). Die Wirtschaftlichkeit von Arzneimitteltherapien am Beispiel von Pravastatin: Eine sozioökonomische Analyse der CSE-Hemmung bei KHK-Patienten. Medizinische Klinik - Intensivmedizin und Notfallmedizin. 92(6). 363–369. 1 indexed citations
19.
Pasquinelli, C, Kyong‐Mi Chang, Luca G. Guidotti, et al.. (1997). Hepatitis C Virus Core and E2 Protein Expression in Transgenic Mice. Hepatology. 25(3). 719–727. 109 indexed citations
20.
Berger, Karin & W Ehrengut. (1971). [Vaccination lesions and vaccinia-strains].. PubMed. 96(38). 1511–1511.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Éric Rosenthal Breakdown of academic impact, for papers by Françoise Roudot‐Thoraval Breakdown of academic impact, for papers by Giovanni Casazza Breakdown of academic impact, for papers by Junko Tanaka Breakdown of academic impact, for papers by Harold O. Conn Breakdown of academic impact, for papers by Nancy Agmon‐Levin Breakdown of academic impact, for papers by Qin Ning Breakdown of academic impact, for papers by Robert J. de Knegt Breakdown of academic impact, for papers by Fernando Álvarez Breakdown of academic impact, for papers by Manuel Pascual
Rankless by CCL
2026